Proteios Chimera Platform
Proteios is developing research-scale kits for the purification of low-expressed recombinant proteins and the purification of high-expressed recombinant proteins. We are also developing preparative kits for larger capacity purifications and looking to work with manufacturing partners to scaling-up for the purification of biopharmaceuticals during manufacturing.
Proteios is developing a bench-prototype for the cGMP manufacturing of autologous cell therapies (CAR-T) and allogeneic cell therapies (Natural Killer (NK) Cells). The instrument is fully automated – from cell separation to cell therapy formulation and is scalable to handle various volumes of cell source inputs. The instrument can handle multiple cell sources as input - blood, PBMC or leukopaks. The instrument incorporates Proteios’ proprietary multivariate cell separation, in which the separation of cell subpopulations occurs in parallel – resulting in more viable cell therapies as output. Cell fractions contain only the target cell subpopulations (e.g., no bound antibody or magnetics beads). The system can easily be expanded as patient-processing needs grow with the parallel processing of patient cell therapies.
Proteios is developing a cost-effective and biologically-safe alternative to Protein A/G/L affinity chromatography for the purification of recombinant antibodies. Purification incorporates Proteios’ silica-based resin, which uses biologically-safe reagents for antibody elution.
To get future updates on the applications above, subscribe to our blog!
[jetpack_subscription_form title=”” subscribe_text=”” subscribe_button=”Sign Me Up”]
Applications Enabled by the Proteios Platform
The Proteios Platform is based on a patented Proteios Chimera – a two-headed affinity tag which reversibly binds to silica on one end (the anchor) and selectively binds to biologicals on the other end (the tail) – and the silica-based Proteios Resin. The anchor is a proprietary dodecapeptide (Proteios Car9) which exhibits micromolar affinity to silica and provides a flexible and scalable platform technology for the manipulation of biologicals. The tail is a proprietary ssDNA oligo capable of reversibly binding to its target biological with high affinity and specificity. Some applications which have been demonstrated using the Proteios Platform include: recombinant protein purification, isolation of CD4+ and CD8+ T cells for the production of CAR-T cell therapies, recombinant antibody purification, biosensors for diagnostics, and microarray spotting for high-throughput screening.
Proteios will soon be launching research-scale recombinant protein purification kits for low-expressed proteins and high-expressed proteins. The kits are based on the Proteios Car9 affinity tag and our silica-based Proteios Resin. If you are interested in beta-testing these protein purification kits or if you would like to partner to conduct a pilot study for the industrial-scale purification of your biopharmaceutical – please contact us.
Proteios is working to make autologous and allogeneic cell therapies widely available and affordable by providing preclinical and clinical scientists – as well as commercial cell therapy manufacturers – with a modular and scalable manufacturing solution. Proteios’ multivariate cell separation kits enable the parallel isolation of cell subpopulations for the discovery of new cell therapies.
Proteios is developing an alternative to Protein A affinity chromatography for the purification of recombinant antibodies. Using cost-effective and biologically-safe reagents, Proteios’ purification method removes the purification bottleneck during the manufacturing of antibody therapeutics.